Pfizer Inc. announced that Frank D?Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company. Pfizer has initiated an external search for a new Chief Financial Officer and D?Amelio has agreed to stay on board through this process and serve in a consulting role through the transition. With D?Amelio?s planned departure, and his significant contributions to Pfizer?s manufacturing capabilities, the Company has made the decision to name Mike McDermott, Executive Vice President, Chief Global Supply Officer and to have him join Pfizer?s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla, effective January 1, 2022. Frank D?Amelio joined Pfizer in 2007 and during his tenure as Chief Financial Officer the Company has generated close to $150 billion in market cap growth. He has regularly been named one of America?s top CFOs. D?Amelio led multiple acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions such as the acquisition of Wyeth, that was essential in bringing talent and a leading vaccine platform to Pfizer, as well as the divestitures of the animal health, consumer health and mature products businesses that helped further focus the Company on scientific innovation. D?Amelio has created a world class Finance function at Pfizer and many of his team members have also become Chief Financial Officers in other companies. More recently, D?Amelio oversaw Pfizer?s manufacturing network and helped guide the organization through one of its most challenging periods as it worked to address the COVID-19 crisis.